Skip to content
★ Sign in to follow
CF

Christopher Forbes

Eloxx Pharmaceuticals, Inc.
Total declarations
74
Company
1
▲ Purchases (69 ops.)
€454k
▼ Sales (0 ops.)
—

Latest filing published 26 Nov 2012 for Eloxx Pharmaceuticals, Inc., €309.

Insider track record

Disclosed buys
69
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
69
Positive at T+90
88%
Median T+90
+44.5%

Based on 17 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Christopher Forbes: trading record in brief

This profile gathers the share dealings of Christopher Forbes in Eloxx Pharmaceuticals, Inc. In total, 74 filings cover trades dated from 17 March 2006 to 26 November 2012.

Every open-market trade on record is a purchase: 69 purchases worth €454k, and no sale. The amount is not disclosed for 3 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants. In 2012 alone, the filings show 2 purchases and no sales.

The median purchase comes to €1,382. Looking at 17 purchases old enough to measure, the stock rose over the following 90 days in 88% of cases; the median change was +44.5%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 26 November 2012, the filings show an open-market purchase worth €309 in Eloxx Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Christopher Forbes

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations74 total

25 of 74 declarations